	US 12,264,189 B2
	Methods and materials for treating cancer
Saad J. Kenderian, Rochester, MN (US); and Stephen James Russell, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Appl. No. 17/287,164
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
PCT Filed Oct. 31, 2019, PCT No. PCT/US2019/059260 § 371(c)(1), (2) Date Apr. 21, 2021, PCT Pub. No. WO2020/092839, PCT Pub. Date May 7, 2020.
Claims priority of provisional application 62/753,732, filed on Oct. 31, 2018.
Prior Publication US 2021/0355190 A1, Nov. 18, 2021
Int. Cl. C07K 14/705 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C12N 7/00 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/70503 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C12N 7/00 (2013.01); A61K 38/00 (2013.01); A61K 2239/48 (2023.05)]

10 Claims

1. A method for generating T cells expressing a selected antigen receptor in vivo within a mammal, wherein said method comprises administering a viral particle to said mammal, wherein said viral particle comprises (a) nucleic acid encoding said selected antigen receptor and (b) an exogenous polypeptide capable of being encoded by SEQ ID NO:2, wherein said viral particle infects T cells comprising an endogenous T cell receptor within said mammal to form infected T cells, and wherein said infected T cells express said selected antigen receptor and said endogenous T cell receptor.